GeneLeap Announces Novel GalNAc Synthesis and Evaluation in Mice as Antisense Oligonucleotide Conjugates at ACS 2021
News provided by
Share this article
Share this article
BOSTON, April 25, 2021 /PRNewswire/ -- GeneLeap Biotech, a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an e-poster entitled '
Design and synthesis of novel GalNAc linker moieties, conjugation to antisense oligonucleotides and evaluation in mice' at the Spring Meeting of the American Chemical Society (ACS) 2021. The study reported new synthetic methodologies for the synthesis of novel tri-antennary GalNAc units and their evaluation for delivery and efficacy as GalNAc-antisense oligo conjugates in mice.